Fmr LLC trimmed its holdings in shares of Intrexon Corporation (NYSE:XON) by 6.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 5,597,513 shares of the biotechnology company’s stock after selling 384,889 shares during the period. Fmr LLC owned approximately 4.68% of Intrexon Corporation worth $134,844,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in XON. Synovus Financial Corp increased its position in shares of Intrexon Corporation by 0.6% during the second quarter. Synovus Financial Corp now owns 33,613 shares of the biotechnology company’s stock valued at $810,000 after acquiring an additional 200 shares in the last quarter. Alliancebernstein L.P. increased its position in shares of Intrexon Corporation by 0.6% during the second quarter. Alliancebernstein L.P. now owns 32,610 shares of the biotechnology company’s stock valued at $786,000 after acquiring an additional 200 shares in the last quarter. Legal & General Group Plc increased its position in shares of Intrexon Corporation by 2.1% during the second quarter. Legal & General Group Plc now owns 18,843 shares of the biotechnology company’s stock valued at $454,000 after acquiring an additional 393 shares in the last quarter. CWM LLC increased its position in shares of Intrexon Corporation by 1.7% during the second quarter. CWM LLC now owns 36,143 shares of the biotechnology company’s stock valued at $871,000 after acquiring an additional 597 shares in the last quarter. Finally, Pacer Advisors Inc. increased its position in shares of Intrexon Corporation by 21.6% during the first quarter. Pacer Advisors Inc. now owns 7,352 shares of the biotechnology company’s stock valued at $146,000 after acquiring an additional 1,305 shares in the last quarter. Hedge funds and other institutional investors own 82.11% of the company’s stock.

Shares of Intrexon Corporation (NYSE:XON) opened at 19.17 on Friday. The company’s 50 day moving average is $19.08 and its 200 day moving average is $21.09. The company’s market cap is $2.31 billion. Intrexon Corporation has a 12 month low of $17.03 and a 12 month high of $32.90.

Intrexon Corporation (NYSE:XON) last posted its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.05. Intrexon Corporation had a negative net margin of 60.63% and a negative return on equity of 19.08%. The company had revenue of $54.40 million during the quarter, compared to analysts’ expectations of $57.17 million. During the same quarter in the prior year, the company posted ($0.42) earnings per share. Intrexon Corporation’s revenue for the quarter was up 3.6% compared to the same quarter last year. On average, equities research analysts predict that Intrexon Corporation will post ($0.87) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.dailypolitical.com/2017/10/07/fmr-llc-sells-384889-shares-of-intrexon-corporation-xon.html.

XON has been the subject of several analyst reports. Northland Securities reissued a “buy” rating and set a $27.00 price target on shares of Intrexon Corporation in a research report on Friday. Griffin Securities reissued a “buy” rating and set a $55.00 price target on shares of Intrexon Corporation in a research report on Friday. BidaskClub raised shares of Intrexon Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. JMP Securities reissued an “outperform” rating and set a $42.00 price target on shares of Intrexon Corporation in a research report on Thursday. Finally, Zacks Investment Research downgraded shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. Intrexon Corporation has a consensus rating of “Hold” and an average target price of $43.20.

In other news, COO Andrew J. Last bought 2,000 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The stock was bought at an average price of $19.99 per share, with a total value of $39,980.00. Following the completion of the transaction, the chief operating officer now directly owns 2,000 shares of the company’s stock, valued at approximately $39,980. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert B. Shapiro bought 2,850 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were purchased at an average cost of $17.50 per share, with a total value of $49,875.00. Following the transaction, the director now directly owns 43,157 shares of the company’s stock, valued at $755,247.50. The disclosure for this purchase can be found here. Insiders have purchased 144,569 shares of company stock valued at $2,719,429 in the last three months. 55.10% of the stock is currently owned by corporate insiders.

Intrexon Corporation Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corporation (NYSE:XON).

Institutional Ownership by Quarter for Intrexon Corporation (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.